Novavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 4,600 Shares

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 4,600 shares of the business’s stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $8.48, for a total value of $39,008.00. Following the sale, the director now owns 57,160 shares in the company, valued at approximately $484,716.80. The trade was a 7.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Novavax Price Performance

Shares of NVAX opened at $8.85 on Friday. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -3.92 and a beta of 2.07. Novavax, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $23.86. The business’s 50-day moving average is $8.69 and its 200-day moving average is $11.34.

Novavax (NASDAQ:NVAX) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to analyst estimates of $65.80 million. Novavax’s revenue for the quarter was down 54.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.26) EPS. Equities research analysts expect that Novavax, Inc. will post -1.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novavax

A number of hedge funds have recently added to or reduced their stakes in the company. Shah Capital Management increased its holdings in Novavax by 19.0% in the second quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company’s stock worth $122,322,000 after buying an additional 1,544,263 shares during the last quarter. State Street Corp increased its holdings in Novavax by 26.7% in the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock worth $97,099,000 after buying an additional 1,621,772 shares during the last quarter. Geode Capital Management LLC increased its holdings in Novavax by 9.5% in the third quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company’s stock worth $44,245,000 after buying an additional 304,159 shares during the last quarter. Bank of Montreal Can increased its holdings in Novavax by 26.7% in the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock worth $32,643,000 after buying an additional 517,727 shares during the last quarter. Finally, Two Sigma Advisers LP increased its holdings in Novavax by 48.9% in the third quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock worth $25,252,000 after buying an additional 656,900 shares during the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on NVAX. B. Riley restated a “buy” rating and set a $26.00 price objective (up previously from $23.00) on shares of Novavax in a report on Thursday, October 10th. Jefferies Financial Group cut their price objective on Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, October 16th. Finally, HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Novavax has an average rating of “Hold” and a consensus price target of $17.83.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.